Company intelligence / Profile preview
CJ Corporation
- Ownership
- Private
- Development stage
- Other
Overview
CJ Corporation is a major South Korean conglomerate with significant activities in life sciences through its pharmaceutical and biotech arms. Its subsidiary companies have developed antibiotics, vaccines—including one of the world’s first alpha-interferon drugs—and are now global leaders in microbiome-based therapeutics R&D. The group leverages advanced bioinformatics platforms for both diagnostics and therapeutic development. Clinical results from recent years include ongoing multinational trials targeting solid tumors with live biotherapeutic products/microbiome therapies; historical success includes commercialization of vaccines like Hepaccine-B against hepatitis B.
- Therapeutic areas
- OncologyGastroenterologyNeurologyInfectious Diseases
- Modalities
- Small moleculeVaccineBiologicMicrobial therapyAntibioticsRecombinant protein
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on CJ Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CJ Corporation.